GlassScriptPhysician profile
Terry Kanefsky
NPI 1124035589
$383.82
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $37.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $112.01 | 2019 | |
| Medtronic Minimed, INC. | $68.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.02 | 2019 | |
| Shire North American Group INC | $28.75 | 2019 | |
| Novo Nordisk INC | $24.74 | 2019-2020 | |
| Valeritas, INC. | $23.40 | 2019 | |
| Abbvie INC. | $21.54 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.78 | 2019 | |
| Becton, Dickinson and Company | $14.78 | 2019 | |
| Radius Health, INC. | $13.99 | 2019 | |
| Dexcom, INC. | $12.85 | 2020 | |
| Corcept Therapeutics | $12.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Kanefsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.